- In June 2024, Charles River Laboratories announced a strategic collaboration with the Gates Institute at the University of Colorado Anschutz Medical Campus to enhance lentiviral vector production, aiming to advance gene therapy research and development
- In May 2024, Donaldson Company, Inc. revealed the development of an integrated lentiviral vector manufacturing platform through its subsidiaries, Isolere Bio and Univercells Technologies, focusing on improving production efficiency and scalability
- In September 2024, Rentschler Biopharma introduced a new lentiviral vector manufacturing toolbox at its Stevenage, UK site, expanding its service offerings to support advanced therapy developers with process development and cGMP manufacturing services
- In December 2024, VIVEbiotech secured growth equity investment from Ampersand Capital Partners to expand its lentiviral vector manufacturing capabilities in San Sebastián, Spain, supporting a robust pipeline of gene therapy projects
- In June 2024, Rocket Pharmaceuticals announced that the U.S. FDA declined to approve its gene therapy, Kresladi, for treating severe Leukocyte Adhesion Deficiency-I, requesting additional information to complete its review
